Showing 13 to 24 of 123 results
UK Companies Mislead Parents with Unproven Tooth Stem Cell Treatments
Three UK companies are misleading parents by marketing tooth stem cell banking as a treatment for diabetes and autism, costing approximately £1,900, despite expert claims of a lack of supporting evidence, raising ethical concerns.
UK Companies Mislead Parents with Unproven Tooth Stem Cell Treatments
Three UK companies are misleading parents by marketing tooth stem cell banking as a treatment for diabetes and autism, costing approximately £1,900, despite expert claims of a lack of supporting evidence, raising ethical concerns.
Progress
52% Bias Score
Novo Nordisk Offers $499 Ozempic to US Patients
Novo Nordisk is offering a monthly supply of Ozempic for $499 to US patients who pay out-of-pocket, responding to President Trump's calls to lower drug costs and addressing sales impacts from compounding pharmacies.
Novo Nordisk Offers $499 Ozempic to US Patients
Novo Nordisk is offering a monthly supply of Ozempic for $499 to US patients who pay out-of-pocket, responding to President Trump's calls to lower drug costs and addressing sales impacts from compounding pharmacies.
Progress
40% Bias Score
GLP-1 Weight Loss Drugs: Significant Muscle Loss Risk
Over 15 million Americans use GLP-1 drugs for weight loss, but these medications can cause significant muscle loss (15-60% of weight lost), impacting strength and potentially leading to falls and functional decline, especially in older adults. To mitigate this, strength training and a high-protein d...
GLP-1 Weight Loss Drugs: Significant Muscle Loss Risk
Over 15 million Americans use GLP-1 drugs for weight loss, but these medications can cause significant muscle loss (15-60% of weight lost), impacting strength and potentially leading to falls and functional decline, especially in older adults. To mitigate this, strength training and a high-protein d...
Progress
52% Bias Score
Gut Bacteria Linked to Lower Body Fat, Promising New Weight-Loss Treatment
Researchers at the University of Copenhagen discovered that *Ruminococcus torques*, a gut bacterium, produces Rordep1 and Rordep2, molecules that promote weight loss by mimicking irisin and influencing appetite-regulating hormones; clinical trials are now underway to explore this bacterium's potenti...
Gut Bacteria Linked to Lower Body Fat, Promising New Weight-Loss Treatment
Researchers at the University of Copenhagen discovered that *Ruminococcus torques*, a gut bacterium, produces Rordep1 and Rordep2, molecules that promote weight loss by mimicking irisin and influencing appetite-regulating hormones; clinical trials are now underway to explore this bacterium's potenti...
Progress
48% Bias Score
Eli Lilly's Oral GLP-1 Pill Shows Significant Weight Loss in Phase 3 Trial
Eli Lilly announced positive Phase 3 trial results for its oral GLP-1 obesity drug, orforglipron, showing a 12.4% average weight loss in 3,127 obese adults (excluding diabetics) after 72 weeks, with 59.6% losing at least 10% of their body weight and 39.6% losing at least 15%, and fewer cardiovascula...
Eli Lilly's Oral GLP-1 Pill Shows Significant Weight Loss in Phase 3 Trial
Eli Lilly announced positive Phase 3 trial results for its oral GLP-1 obesity drug, orforglipron, showing a 12.4% average weight loss in 3,127 obese adults (excluding diabetics) after 72 weeks, with 59.6% losing at least 10% of their body weight and 39.6% losing at least 15%, and fewer cardiovascula...
Progress
40% Bias Score
Type 5 Diabetes: A New Form Affecting Underweight Individuals
A new type of diabetes, Type 5, has been identified affecting underweight individuals with low BMIs, particularly in low-to-middle income countries, challenging the common understanding of diabetes and necessitating further research.
Type 5 Diabetes: A New Form Affecting Underweight Individuals
A new type of diabetes, Type 5, has been identified affecting underweight individuals with low BMIs, particularly in low-to-middle income countries, challenging the common understanding of diabetes and necessitating further research.
Progress
36% Bias Score
CGM Market Booms as Wellness Trend Gains Momentum
The global market for continuous glucose monitors (CGMs) is booming, reaching \$4.6 billion in 2023 and projected to hit \$7.51 billion by 2030, driven by increased consumer access and social media marketing; however, users should be aware of potential inaccuracies and the need for medical guidance.
CGM Market Booms as Wellness Trend Gains Momentum
The global market for continuous glucose monitors (CGMs) is booming, reaching \$4.6 billion in 2023 and projected to hit \$7.51 billion by 2030, driven by increased consumer access and social media marketing; however, users should be aware of potential inaccuracies and the need for medical guidance.
Progress
40% Bias Score
Novo Nordisk Offers $499 Ozempic to US Patients
Novo Nordisk is offering Ozempic for $499 per month to US patients paying out-of-pocket, responding to political pressure to lower drug costs and competition from compounding pharmacies.
Novo Nordisk Offers $499 Ozempic to US Patients
Novo Nordisk is offering Ozempic for $499 per month to US patients paying out-of-pocket, responding to political pressure to lower drug costs and competition from compounding pharmacies.
Progress
40% Bias Score
Aggressive Treatment Recommended for Heart Disease Patients with Diabetes
New guidelines recommend aggressive treatment for heart disease patients with diabetes, emphasizing SGLT2 inhibitors and GLP-1 receptor agonists to reduce cardiovascular risks, alongside a Mediterranean diet; published May 12, 2020, in Circulation.
Aggressive Treatment Recommended for Heart Disease Patients with Diabetes
New guidelines recommend aggressive treatment for heart disease patients with diabetes, emphasizing SGLT2 inhibitors and GLP-1 receptor agonists to reduce cardiovascular risks, alongside a Mediterranean diet; published May 12, 2020, in Circulation.
Progress
36% Bias Score
Eli Lilly's Orforglipron Shows Promise in Weight Loss Trial
Eli Lilly's Phase 3 trial of Orforglipron, an oral GLP-1 receptor agonist for weight loss, showed a 12.4% average weight loss in obese adults after 72 weeks, prompting plans for FDA approval by year's end; however, experts voice concerns about the yo-yo effect and lack of comparison to effective non...
Eli Lilly's Orforglipron Shows Promise in Weight Loss Trial
Eli Lilly's Phase 3 trial of Orforglipron, an oral GLP-1 receptor agonist for weight loss, showed a 12.4% average weight loss in obese adults after 72 weeks, prompting plans for FDA approval by year's end; however, experts voice concerns about the yo-yo effect and lack of comparison to effective non...
Progress
44% Bias Score
Metformin Linked to Lower Dementia Risk in Overweight and Obese Individuals
A study of half a million overweight and obese individuals revealed that metformin users had a significantly lower risk of developing dementia and death from any cause, with the greatest benefits observed in those with BMIs between 25 and 34.9.
Metformin Linked to Lower Dementia Risk in Overweight and Obese Individuals
A study of half a million overweight and obese individuals revealed that metformin users had a significantly lower risk of developing dementia and death from any cause, with the greatest benefits observed in those with BMIs between 25 and 34.9.
Progress
40% Bias Score
Genetic Switches of Hibernation Could Unlock Treatments for Age-Related Diseases
Researchers have discovered key genetic switches in hibernating animals that control metabolic processes, potentially unlocking treatments for age-related diseases like diabetes and neurodegeneration by manipulating gene expression.
Genetic Switches of Hibernation Could Unlock Treatments for Age-Related Diseases
Researchers have discovered key genetic switches in hibernating animals that control metabolic processes, potentially unlocking treatments for age-related diseases like diabetes and neurodegeneration by manipulating gene expression.
Progress
24% Bias Score
Showing 13 to 24 of 123 results